228 related articles for article (PubMed ID: 19491200)
1. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
[TBL] [Abstract][Full Text] [Related]
2. Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.
Eischen CM; Boyd K
PLoS One; 2012; 7(9):e46148. PubMed ID: 23029416
[TBL] [Abstract][Full Text] [Related]
3. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
4. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation.
Sashida G; Liu Y; Elf S; Miyata Y; Ohyashiki K; Izumi M; Menendez S; Nimer SD
Mol Cell Biol; 2009 Jul; 29(13):3687-99. PubMed ID: 19380490
[TBL] [Abstract][Full Text] [Related]
5. Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.
Ta VB; de Bruijn MJ; ter Brugge PJ; van Hamburg JP; Diepstraten HJ; van Loo PF; Kersseboom R; Hendriks RW
Blood; 2010 Feb; 115(7):1385-93. PubMed ID: 20008789
[TBL] [Abstract][Full Text] [Related]
6. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
8. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF.
Wang P; Greiner TC; Lushnikova T; Eischen CM
Oncogene; 2006 Jun; 25(26):3708-18. PubMed ID: 16491126
[TBL] [Abstract][Full Text] [Related]
9. MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal.
Schuster K; Fan L; Harris LC
Mol Cancer Res; 2007 Apr; 5(4):403-12. PubMed ID: 17426254
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts.
Bandopadhayay P; Jabbour AM; Riffkin C; Salmanidis M; Gordon L; Popovski D; Rigby L; Ashley DM; Watkins DN; Thomas DM; Algar E; Ekert PG
BMC Cancer; 2013 Dec; 13():585. PubMed ID: 24321497
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.
Inoue K; Wen R; Rehg JE; Adachi M; Cleveland JL; Roussel MF; Sherr CJ
Genes Dev; 2000 Jul; 14(14):1797-809. PubMed ID: 10898794
[TBL] [Abstract][Full Text] [Related]
12. A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis.
Sinha VC; Qin L; Li Y
Mol Cancer Res; 2015 Feb; 13(2):231-8. PubMed ID: 25253740
[TBL] [Abstract][Full Text] [Related]
13. The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression.
Pan W; Issaq S; Zhang Y
PLoS One; 2011; 6(6):e21625. PubMed ID: 21747916
[TBL] [Abstract][Full Text] [Related]
14. Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of
van Oosterwijk JG; Li C; Yang X; Opferman JT; Sherr CJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7420-7425. PubMed ID: 28652370
[TBL] [Abstract][Full Text] [Related]
15. MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence.
Volk EL; Schuster K; Nemeth KM; Fan L; Harris LC
Dis Model Mech; 2009; 2(1-2):47-55. PubMed ID: 19132120
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
Lin AW; Lowe SW
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
[TBL] [Abstract][Full Text] [Related]
17. p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms.
Widau RC; Zheng Y; Sung CY; Zelivianskaia A; Roach LE; Bachmeyer KM; Abramova T; Desgardin A; Rosner A; Cunningham JM; Skapek SX
Mol Cell Biol; 2012 Nov; 32(21):4270-82. PubMed ID: 22907756
[TBL] [Abstract][Full Text] [Related]
18. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
Zhang Y; Xiong Y
Cell Growth Differ; 2001 Apr; 12(4):175-86. PubMed ID: 11331246
[TBL] [Abstract][Full Text] [Related]
19. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
[TBL] [Abstract][Full Text] [Related]
20. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.
Cheng X; Xia W; Yang JY; Hsu JL; Lang JY; Chou CK; Du Y; Sun HL; Wyszomierski SL; Mills GB; Muller WJ; Yu D; Hung MC
Cancer Res; 2010 Oct; 70(19):7684-9. PubMed ID: 20841468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
